glp-1 news november 3 2025 The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs At 'Most Favored Nation' prices,

There are over 100 clinical studies in the pipeline right now

Introduction The obesity and metabolic disease epidemic continues to surge, with over 40% of U.S

[DOI] [PubMed] [Google Scholar] 33.Wettergren A, Wjdemann M, Holst JJ

For this reason, the investigators modeled weight rebound on a continuous trajectory using available follow-up data from the included studies

[38] Bupropion was originally called by the generic name amfebutamone, before being renamed in 2000

Germany Focuses on Private Sector Treatment Access Demand for obesity GLP-1 treatment in Germany is projected to grow at a CAGR of 19.6%, constrained by statutory health insurance exclusions for anti-obesity medications that limit public reimbursement